ADMS News and Press, Adamas Pharmaceuticals Inc. From 02/20/19

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, C...

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results on Monday, March 4, 2019, after market close. Subsequently, Adamas’ management team will h...

NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Roku, Inc. (NASDAQ:ROKU), AECOM (NYSE:ACM), 1-800 FLOWERS.COM, Inc. (N...

Amarin ( AMRN ) has been a darling of biotech investors with one of the highest bullish sentiments that I have seen on a stock. I will not go into the details of the background of this stock since I assume that you are familiar with it. Amarin's sole product Vascepa has a proprietary formulati...

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up...

Adamas Pharmaceuticals (NASDAQ: ADMS ) outlines key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI (amantadine) extended release capsules. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect ...

Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS...

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more ...

More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more ...